Another drug to fight severe COVID

More good news !

The new drug for COVID is called baricitinib.

The drug Baricitinib is not a brand new drug. It is normally used to treat a type of joint problem called rheumatoid arthritis. Now, this drug has been found to be very beneficial in patients suffering from severe COVID.

The drug was evaluated as part of the renowned RECOVERY trial.

RECOVERY ( Randomised Evaluation of Covid-19 Therapy) trial is led by investigators in U.K.

The trial found that Baricitinib reduces the risk of death by around one fifth in patients with severe covid-19.

On the other hand, Some bad news about a drug who was thought to be promising before. Questions have been raised about the actual benefit , if any, from a previously approved drug called Molnupiravir.

Overall, at present, we have lot more drugs to tackle COVID in addition to the Vaccines.


BMJ. Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial
BMJ 2022; 376 doi: (Published 03 March 2022)
Cite this as: BMJ 2022;376:o573

BBC news. Another life-saving Covid drug identified
By Michelle Roberts
Digital health editor

Guardian. Arthritis drug could help save Covid patients – study
Rheumatoid arthritis drug baricitinib can reduce risk of death from severe Covid by about a fifth
Nicola Davis Science correspondent
Thu 3 Mar 2022 18.07 GMT

Daily Mail. Arthritis drug cuts risk of severely-ill Covid patients dying by up to a fifth, major trial reveals. By Luke Andrews Health Reporter For Mailonline
15:00, 03 Mar 2022 , updated 16:42, 03 Mar 2022

BMJ. Molnupiravir’s authorisation was premature
BMJ 2022; 376 doi: (Published 03 March 2022)
Cite this as: BMJ 2022;376:o443

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.